Hagens Berman Reminds MoonLake Investors of Deadline for Lead Plaintiff in Class Action Lawsuit
Deadline Alert for MoonLake Investors
Hagens Berman, a global plaintiffs' rights law firm, is reminding all investors involved with MoonLake Immunotherapeutics (NASDAQ: MLTX) that the deadline for becoming a Lead Plaintiff in the ongoing securities class action lawsuit is set for December 15, 2025. The lawsuit focuses on allegations that the company and its executives made false and misleading statements about the clinical capabilities of their primary drug candidate, sonelokimab (SLK), leading to a shocking almost 90% drop in stock prices in September 2025.
Overview of Allegations Against MoonLake
The legal action primarily centers on claims made by MoonLake that its Nanobody technology, particularly sonelokimab, would outperform traditional monoclonal antibody treatments, including the FDA-approved BIMZELX. Investors were assured that this innovative treatment would deliver superior clinical efficacy characterized by significantly higher response rates. Unfortunately, this confidence was shattered when the disappointing results from the Phase 3 VELA-2 trial were made public, showcasing inferior efficacy in comparison to competitors.
According to Reed Kathrein, a partner at Hagens Berman and the leading attorney in this case, “We are focusing on the repeated assurances MoonLake gave investors about the supposed ‘superiority’ of their Nanobody technology. When the VELA-2 results came out, those promises evaporated, and investors lost nearly everything overnight.” This stark collapse signals the importance of acting swiftly if you experienced significant losses.
Key Details of the Lawsuit
The timeline of events is critical here:
- - Class Period: March 10, 2024 – September 29, 2025
- - Lead Plaintiff Deadline: December 15, 2025
- - Stock Drop Event: On September 29, 2025, MoonLake's stock plummeted from $61.99 to $6.24 after the disappointing results from the VELA-2 trial.
The lawsuit contends that the firm’s prior statements lead investors to believe in the strong clinical efficacy of SLK, a belief that turned out to be grossly misleading.
Next Steps for Affected Investors
Investors who purchased shares in MoonLake between March 10, 2024, and September 29, 2025, and who registered significant losses, are highly encouraged to contact Hagens Berman immediately. This is your opportunity to discuss potential legal options and determine eligibility for appointment as Lead Plaintiff, which could be a crucial step for seeking recoveries from the firm.
Additionally, those who possess credible non-public information regarding MoonLake could explore the SEC Whistleblower program, which may yield significant rewards for cooperation.
About Hagens Berman
Founded on the principles of corporate accountability, Hagens Berman operates nationally and specializes in complex litigation, particularly regarding investors and consumers victimized by corporate negligence. They have successfully recovered over $2.9 billion for clients to date, navigating intricate legal landscapes to advocate for right and justice. Further updates about the firm and its cases are accessible at hbsslaw.com.
For further inquiries or to discuss potential claims, you can reach out to Reed Kathrein via email at [email protected] or call 844-916-0895.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.